Clarithromycin.|81103-11-9|(克拉霉素)-陌孚医药/Medlife

您当前的位置：

Clarithromycin. (Synonyms: 克拉霉素)

目录号: PC12486 纯度: ≥98%

CAS No. :81103-11-9

商品编号	规格	价格	会员价
PC12486-100mg	100mg	¥588.00	请登录
PC12486-200mg	200mg	¥980.00	请登录
PC12486-10mM (in 1mL DMSO)	10mM (in 1mL DMSO)	¥588.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称

Clarithromycin.

中文别名

克拉霉素;甲氧基红霉素;甲基红霉素;克拉红霉素;克拉仙;克拉仙霉素;克红霉素;克拉霉素 GMP;Clarithromycin 克拉霉素;甲红霉素;克拉红霉素拉霉素;克拉红霉素及杂质;克拉霉素 EP标准品;克拉霉素 USP标准品;克拉霉素标准品;克拉霉素-13C-D3;克拉霉素峰鉴别 EP标准品;克拉霉素鉴别用 USP标准品;克拉霉素鉴别用标准品;克拉霉素原药;盐酸羟苄唑;甲氧基红霉素标准品;克拉红霉素,克拉霉素;克拉霉素克拉仙;克拉霉素酰亚胺;氯甲亚胺硫磷;氯亚磷

英文名称

Clarithromycin

英文别名

Clarithromycin;Naxy;Clarithromycin-13C-d3;6-O-metkylerythromycin;Biaxin;Claric;Claris;ClarithroMycin Identity;Clarosip;Clathromycin;Cyllind;Klacid;Kladd;Klar-icid;Macladin;te-03;TE-031;Veclam;Zeciar;Zeclar;6-O-Methylerythromycin;A-56268;Klaricid;6-O-Methylerythromycin a;Clarithromycine;Kofron;Clarith;Clarithromycinum;Erythromycin, 6-O-methyl-;Biaxin XL;Fromilid;Claridar;Bicrolid;Astromen;Claricide;Clacine;Abbotic;Mabicrol;Clambiotic;Klaciped;Heliclar;Claripen;Claribid;Clarem;Clacid;Clacee;Maclar;Klarid;Crixan;Klarin;Klabax;Cyllid;Mavid;Helas;Biaxin filmtab;Adel;Klax;Biaxin xl filmtab;Biaxin HP;Klar;Klaricid Pediatric;Clarithromycine [INN-F

Cas No.

81103-11-9

分子式

C₃₈H₆₉NO₁₃

分子量

747.95

包装储存

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

Clarithromycin has a broad spectrum of antimicrobial activity. Clarithromycin inhibits the CYP3A4-catalyzed triazolam alpha-hydroxylation with the IC₅₀ (K_i) value of 56 (43) μM. Clarithromycin significantly inhibits the HERG potassium current.Clarithromycin affects the autophagic flux by impairing the signaling pathway linking hERG1 and PI3K.

性状

Solid

IC50 & Target[1][2]

CYP3

Macrolide

体外研究(In Vitro)

Clarithromycin produces a similar concentration-dependent block with an IC₅₀ of 45.7 μM.
Clarithromycin induces the formation of numerous intracytoplasmic vacuoles after 24?h, in all cell lines, especially in HCT116 cells. Prolonged treatment with Clarithromycin (40, 80, and 160?μM) alters cell proliferation and triggers apoptotic cell death in colorectal cancer (CRC) cells. Inhibition of cell proliferation is potentiated when Clarithromycin is re-added to the cells. In particular, 160?μM Clarithromycin, re-added after 48?h of incubation, produces an arrest of cell proliferation at 72?h. Similar effects are obtained in LS174T cells.
Clarithromycin (80 and 160?μM; 48 hours) strongly increases the LC3-II/LC3-I ratio, in a dose- and time-dependent manner, with a maximum at 24?h of treatment. This effect is accompanied by a decrease of p62/SQSTM1.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	HCT116 cells
Concentration:	40, 80, and 160?μM
Incubation Time:	24, 48, 72?hours
Result:	Reduced HCT116 cell proliferation, although did not completely abolished it.

Western Blot Analysis

Cell Line:	HCT116 cells
Concentration:	80 and 160?μM
Incubation Time:	4, 24, 48 hours
Result:	A decrease of LC3-II and a re-increase of p62/SQSTM1 were observed at 48?hours treatment.

体内研究(In Vivo)

Clarithromycin at 200 mg/kg has activity against four tested in vivo.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old beige (C57BL/6J bg/bg) mice which had been infected with viable M. avium ATCC 49601
Dosage:	50, 100, 200, or 300 mg/kg
Administration:	Administered daily by gavage
Result:	Reduced organ cell counts compared with those in mice given no treatment at all doses. Had activity against three additional MAC isolates (MICs for the isolates ranged from 1 to 4 μg/mL by broth dilution) at 200 mg/kg.

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

ClinicalTrial

参考文献

[1]. D H Peters, et al. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992 Jul;44(1):117-64. [Information]

[2]. X J Zhao, et al. An 体外研究 study on the metabolism and possible drug interactions of rokitamycin, a macrolide antibiotic, using human liver microsomes. Drug Metab Dispos. 1999 Jul;27(7):776-85. [Information]

[3]. Scott J C Stanat, et al. Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem. 2003 Dec;254(1-2):1-7. [Information]

[4]. Giulia Petroni, et al. Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K. Cell Death Dis. 2020 Mar 2;11(3):161. [Information]

[5]. S P Klemens, et al. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother. 1992 Nov;36(11):2413-7. [Information]

溶解度数据

体外研究:

DMSO : 33.33 mg/mL (44.56 mM; Need ultrasonic)

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.3370 mL	6.6849 mL	13.3699 mL
5 mM	0.2674 mL	1.3370 mL	2.6740 mL
10 mM	0.1337 mL	0.6685 mL	1.3370 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.5 mg/mL (3.34 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (3.34 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液
2.

建议依照次序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (3.34 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (3.34 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (3.34 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.34 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation